Download TTCC History

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project

page
1
page
2
page
3
page
4
page
5
page
6
page
7
page
8
Document related concepts
no text concepts found
Transcript 
SPANISH HEAD AND NECK
CANCER COOPERATIVE
GROUP (TTCC)
February 2000
2001
1st International Head & Neck Symposium
Cooperative Group with 15 members
National Symposiums TTCC
2005_Barcelona
2007_Salamanca
2009_Zaragoza
2011_Valencia
ACTIVITIES
TRAINING
DISCLOSURE
PREVENTION
DIAGNOSIS
TREATMENT
Clinical Trials
PREVENTION, PRESERVATION,
LOCOREGIONAL AND
METASTASIC
Closed: 5
Opened: 3
Approved by the CEC: 2
Over 1.000 patients
BASIC AND TRASLACIONAL
INVESTIGATION
QTI / NEW MEDICAMENTS
MOLECULAR TARGETS
RDT
QTRDT
RT-E
SUPPORT
SURGERY
A randomized phase II, multicenter trial of induction with Cisplatin/ Docetaxel verus Cisplatin/5-fluorouracil for patients with
locally advanced head and neck carcinoma.
February 2000 and July 2001, 84 patients
TAX-ES-202. Published in Eur J Cancer. 2005 Jun;41(9):1254-60.
A
randomized, multicenter phase III trial comparing induction chemotherapy with Cisplatin/5-FU (PF) or
Docetaxel/Cisplatin/5-FU (TPF) plus chemotherapy (CRT) versus CRT alone as fisrt-line treatment of unresectable
locally advanced head and neck cancer.
XRP6976F / 2503. COMUNICACIÓN ORAL ASCO 2006.
Phase II study of combination Cetuximab and weekly Paclitaxel in patients with metastatic/recurrent squamous cell
carcinoma of head and neck
ERBITAX. ASCO 2007. Pending of publication
Phase II study of Capecitabine as palliative treatment for patients with squamous head and neck cancer with locoregional
and/or metastatic relapse after previous Platinium-based treatment.
XEL-CYC-TTCC. POSTER ASCO 2009. Pending of publication
A single arm, multicenter, phase II trial to evaluate the combination of cetuximab plus taxotere (T), cisplatin (P) and 5fluorouracil (F) (TPF) as induction chemotherapy in patients (pts) with unresectable squamous cell carcinoma of the
head and neck.
NEO-TPFE-TTCC. Póster discusión ASCO 2009. Preliminar results
A
randomized, multicenter phase III trial comparing induction chemotherapy with Cisplatin/5-FU (PF) or
Docetaxel/Cisplatin/5-FU (TPF) plus chemotherapy (CRT) versus CRT alone as fisrt-line treatment of unresectable
locally advanced head and neck cancer.
XRP6976F / 2503. COMUNICACIÓN ORAL ASCO 2009. Pending of publication
Open Studies
An Open Label Randomized, Multi-Centre Phase III Trial of TPF Chemotherapy
Plus Concomitant Treatment With Cisplatin and Conventional Radiotherapy
Versus TPF Chemotherapy Plus Concomitant Cetuximab and Conventional
Radiotherapy in Locally Advanced, Un-resectable Head and Neck Cancer.
TTCC-2007-01
(ClinicalTrials.gov Identifier: NCT00716391)
A Phase II Trial With Radiotherapy Plus Cetuximab to Evaluate Specific Survival
Free of Laryngectomy in Patients With Resectable and Locally Advanced
Larynx Cancer, After Treatment With TPF Chemotherapy.
TTCC-2007-02
( ClinicalTrials.gov Identifier: NCT00765011)
An Open Label Randomized, Phase III Trial With Erlotinib (Tarceva®) as
Maintenance Treatment in Patients With Operated Squamous Cell Carcinoma of
the Head and Neck and treated with Chemo-radiotherapy or Radiotherapy with
Curative Purposes.
ML20294
(Nº EudraCT: 2006-001845-33)
PANITUMUMAB
IN METASTASICS
IN LOCALLY ADVANCED
LAPATINIB
THYROIDS CANCER
NASOPHARYNGEAL CANCER
Related documents